Table 3. The association of serum total- and LDL-cholesterol and apolipoprotein B levels with USF1 genotypes and haplotype 3 (H3) according to gender and follow-up year. The Cardiovascular Risk in Young Finns Study.

Follow-up Year	SNP or haplotype	Genotypeor copy of haplotype	N (women)	Mean ± SD	P	N (men)	Mean ± SD	P	N (all)	Mean ± SD	P
Total cholesterol (mmol/L)
2001	rs2516839	TT	349	5.01 ± 0.85	0.67	282	5.27 ± 1.00	0.536	631	5.12 ± 0.93	0.82
		TC	419	5.04 ± 0.89		326	5.18 ± 0.94		745	5.10 ± 0.91
		CC	123	5.09 ± 0.90		96	5.22 ± 1.05		219	5.14 ± 0.97
	rs1556259	AA	665	5.00 ± 0.86	0.041	536	5.23 ± 0.99	0.848	1201	5.10 ± 0.93	0.335
		AG	218	5.10 ± 0.90		150	5.18 ± 0.95		368	5.13 ± 0.92
		GG	12	5.57 ± 1.03		13	5.19 ± 0.65		25	5.37 ± 0.86
	H3	0	670	5.00 ± 0.86	0.047	543	5.23 ± 0.99	0.882	1213	5.10 ± 0.93	0.328
		1	217	5.11 ± 0.90		148	5.18 ± 0.96		365	5.14 ± 0.92
		2	15	5.47 ± 0.97		15	5.22 ± 0.62		30	5.34 ± 0.81
2007	rs2516839	TT	349	4.81 ± 0.80	0.013	282	5.20 ± 0.91	0.392	631	4.98 ± 0.87	0.254
		TC	419	4.93 ± 0.79		326	5.10 ± 0.89		745	5.01 ± 0.84
		CC	123	5.03 ± 0.87		96	5.18 ± 0.90		219	5.10 ± 0.89
	rs1556259	AA	665	4.85 ± 0.80	0.009	536	5.16 ± 0.91	0.443	1201	4.99 ± 0.86	0.182
		AG	218	5.02 ± 0.82		150	5.07 ± 0.85		368	5.04 ± 0.83
		GG	12	5.22 ± 0.97		13	5.31 ± 0.55		25	5.26 ± 0.77
	H3	0	670	4.85 ± 0.80	0.006	543	5.17 ± 0.92	0.336	1213	4.99 ± 0.87	0.129
		1	217	5.02 ± 0.82		148	5.07 ± 0.85		365	5.04 ± 0.83
		2	15	5.23 ± 0.93		15	5.34 ± 0.63		30	5.29 ± 0.78
LDL cholesterol (mmol/L)
2001	rs2516839	TT	349	3.10 ± 0.76	0.57	282	3.45 ± 0.88	0.567	631	3.26 ± 0.84	0.644
		TC	419	3.14 ± 0.73		326	3.38 ± 0.85		745	3.24 ± 0.79
		CC	123	3.18 ± 0.78		96	3.46 ± 0.96		219	3.30 ± 0.87
	rs1556259	AA	665	3.11 ± 0.74	0.011	536	3.42 ± 0.88	0.809	1201	3.25 ± 0.82	0.128
		AG	218	3.18 ± 0.76		150	3.37 ± 0.90		368	3.26 ± 0.83
		GG	12	3.72 ± 0.88		13	3.46 ± 0.79		25	3.58 ± 0.83
	H3	0	670	3.10 ± 0.73	0.015	543	3.43 ± 0.87	0.716	1213	3.25 ± 0.82	0.114
		1	217	3.19 ± 0.77		148	3.37 ± 0.90		365	3.26 ± 0.83
		2	15	3.61 ± 0.85		15	3.51 ± 0.75		30	3.56 ± 0.79
2007	rs2516839	TT	349	2.85 ± 0.69	0.002	282	3.30 ± 0.80	0.619	631	3.05 ± 0.77	0.068
		TC	419	2.96 ± 0.69		326	3.24 ± 0.79		745	3.08 ± 0.75
		CC	123	3.10 ± 0.73		96	3.31 ± 0.79		219	3.19 ± 0.76
	rs1556259	AA	665	2.89 ± 0.68	0.003	536	3.27 ± 0.79	0.276	1201	3.06 ± 0.76	0.026
		AG	218	3.05 ± 0.74		150	3.22 ± 0.78		368	3.12 ± 0.76
		GG	12	3.30 ± 0.75		13	3.57 ± 0.56		25	3.44 ± 0.66
	H3	0	670	2.89 ± 0.68	0.003	543	3.28 ± 0.80	0.160	1213	3.07 ± 0.76	0.022
		1	217	3.05 ± 0.74		148	3.21 ± 0.78		365	3.12 ± 0.76
		2	15	3.26 ± 0.75		15	3.60 ± 0.64		30	3.43 ± 0.71
Apolipoprotein B (g/L)
2001	rs2516839	TT	349	0.97 ± 0.23	0.469	282	1.12 ± 0.26	0.924	631	1.04 ± 0.26	0.886
		TC	419	0.99 ± 0.23		326	1.12 ± 0.24		745	1.05 ± 0.24
		CC	123	1.00 ± 0.23		96	1.11 ± 0.27		219	1.05 ± 0.25
	rs1556259	AA	665	0.98 ± 0.23	0.309	536	1.12 ± 0.26	0.804	1201	1.04 ± 0.25	0.352
		AG	218	0.99 ± 0.24		150	1.11 ± 0.24		368	1.04 ± 0.25
		GG	12	1.08 ± 0.25		13	1.15 ± 0.21		25	1.11 ± 0.23
	H3	0	670	0.98 ± 0.23	0.33	543	1.12 ± 0.26	0.781	1213	1.04 ± 0.25	0.36
		1	217	1.00 ± 0.24		148	1.11 ± 0.25		365	1.04 ± 0.25
		2	15	1.06 ± 0.23		15	1.16 ± 0.20		30	1.11 ± 0.22
2007	rs2516839	TT	349	0.91 ± 0.22	0.015	282	1.11 ± 0.25	0.222	631	1.00 ± 0.25	0.46
		TC	419	0.94 ± 0.22		326	1.08 ± 0.24		745	1.00 ± 0.24
		CC	123	0.98 ± 0.24		96	1.08 ± 0.25		219	1.02 ± 0.25
	rs1556259	AA	665	0.93 ± 0.22	0.049	536	1.10 ± 0.25	0.638	1201	1.00 ± 0.25	0.388
		AG	218	0.96 ± 0.23		150	1.08 ± 0.23		368	1.00 ± 0.24
		GG	12	1.05 ± 0.24		13	1.09 ± 0.20		25	1.07 ± 0.22
	H3	0	670	0.93 ± 0.22	0.055	543	1.10 ± 0.25	0.621	1213	1.00 ± 0.25	0.421
		1	217	0.96 ± 0.23		148	1.08 ± 0.23		365	1.00 ± 0.24
		2	15	1.03 ± 0.23		15	1.09 ± 0.19		30	1.06 ± 0.21

Values are mean ± SD. ANOVA. Significant values within the women strata after correcting for multiple testing (P ≤ 0.015) are in bold.